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Accelerated microﬂuidic native chemical ligation
at difﬁcult amino acids toward cyclic peptides
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Cyclic peptide-based therapeutics have a promising growth forecast that justiﬁes the
development of microﬂuidic systems dedicated to their production, in phase with the actual
transitioning toward continuous ﬂow and microﬂuidic technologies for pharmaceutical pro-
duction. The application of the most popular method for peptide cyclization in water, i.e.,
native chemical ligation, under microﬂuidic conditions is still unexplored. Herein, we report
a general strategy for fast and efﬁcient peptide cyclization using native chemical ligation
under homogeneous microﬂuidic conditions. The strategy relies on a multistep sequence that
concatenates the formation of highly reactive S-(2-((2-sulfanylethyl)amino)ethyl) peptidyl
thioesters from stable peptide amide precursors with an intramolecular ligation step. With
very fast ligation rates (<5 min), even for the most difﬁcult junctions (including threonine,
valine, isoleucine, or proline), this technology opens the door toward the scale-independent,
expedient preparation of bioactive macrocyclic peptides.
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P eptide drugs are an important and fast growing class ofpharmaceuticals1–3, the development of which is stimulatedby (a) the discovery of innovative production methods1, (b)
the design of novel delivery systems4, as well as (c) strategies for
improving their pharmaco-kinetic properties2,5. In particular,
cyclic peptides have been attracting considerable attention for
several decades since they enable higher potency, metabolic sta-
bility, and oral bioavailability than their linear counterparts6,7,
and several of them are already in clinical use8. A large variety of
synthetic methods for producing cyclic peptide scaffolds are now
available9,10. In particular, the two-step process based on the
synthesis of linear peptide precursors by solid phase peptide
synthesis (SPPS11) followed by chemoselective cyclization in
water using either native chemical ligation (NCL12–14), ketoacid
hydroxylamine ligation (KAHA15), or serine/threonine ligation
(STL16) is particularly powerful. Among these methods, the
backbone peptide cyclization using NCL is one of the most
popular17. The NCL reaction involves a sequence of reversible
thiol/thioester exchanges, starting from a peptide alkylthioester,
such as peptide thioester 1 derived from 3-mercaptopropionic
acid (MPA, Fig. 1a). The sequence starts with the exchange
between 1 and a catalyst, e.g., 4-mercaptophenylacetic acid
(MPAA), and then with an N-terminal Cys-peptide to produce a
transient thioester-linked intermediate. The latter undergoes an
irreversible S-to-N acyl shift, leading to the formation of a native
peptide bond to Cys. The intramolecular version of NCL applied
to a peptide featuring an N-terminal Cys residue and a C-
terminal thioester functionality results in the formation of a
backbone cyclized peptide17. One limitation of NCL is the low
reactivity of peptide thioesters containing C-terminal threonine
(Thr, T), valine (Val, V), isoleucine (Ile, I), or proline (Pro, P)
residues (Fig. 1a)18, which is reﬂected by the reluctance of peptide
chemists to produce linear or cyclic peptides through the for-
mation of such difﬁcult junctions19. Therefore, the search for
simple and fast ligation methods is a timely and signiﬁcant goal
that should streamline the production of complex peptides
including cyclic architectures20,21.
In parallel to the development of chemoselective ligation
techniques, the ﬁeld of peptide synthesis has beneﬁted from the
emergence of microﬂuidic and continuous ﬂow technologies
for overcoming known synthetic limitations22, facilitating auto-
mation and enabling an accurate control over the process
parameters23,24. Peptide synthesis using microﬂuidics comes
with a range of inherent assets for meeting high pharmaceutical
standards, such as cleaner and constant reaction proﬁles, fast
lab-to-market transitions, higher space/time yields even for
complex reaction sequences25,26, and on-demand pharmaceutical
production27. Homogeneous microﬂuidic peptide synthesis by
stepwise coupling of protected amino acids was pioneered by
Watts in 200128 and later extended by several groups with
equivalent or superior performances than conventional batch
strategies29–31. Oligopeptide macrocyclization by enthalpic acti-
vation of a linear precursor31 or the SPPS method32–35 were
also transposed under microﬂuidic conditions. However, and
despite a huge preparative potential, NCL has not yet been
adapted under microﬂuidic conditions, whether for peptide
cyclization or for other applications. A close examination of
NCL requirements and general features emphasizes the com-
plexity of transposing such ligation chemistry from batch to
microﬂuidic operation: to be of interest, the system must be
fed with solutions of stable precursors, while reaction kinetics
within the system must be fast enough to be compatible with its
intrinsic features and small internal dimensions. These two
requirements are barely compatible with standard NCL since a
classical peptide alkylthioester, such as 1 (Fig. 1a), will require
extended ligation times, while a reactive arylthioester, such as 2
(Fig. 1a)36, will undergo signiﬁcant hydrolysis in the feed befor-
e entering the microﬂuidic system18. A potential solution is
to feed the system with a stable peptide thioester precursor that
can be activated within a ﬁrst microﬂuidic module, prior to
entering the ligation module for triggering peptide cyclization
(Fig. 1b). Importantly, the solution used for the activation step
must not interfere with the NCL reaction, while the generated
thioester must be a powerful acyl donor to enable ligation in
a few minutes even for difﬁcult junctions. The formation of
difﬁcult junctions in a few minutes was, however, never
observed with the NCL reaction, irrespective of the acyl donor
including bis(2-sulfanylethyl)amido (SEA) thioester surrogates
of type 3 or 4 (Fig. 1c)37. Such fast kinetics could only be
achieved with the diselenide selenoester ligation (DSL21) of pre-
formed peptidyl selenophenyl esters with bis(selenocysteinyl)
peptides.
Here, we report an effective solution for the cyclization of
peptides under microﬂuidic conditions that relies on the
enhanced reactivity of intermediate S-(2-((2-sulfanylethyl)
amino)ethyl) peptidyl (SEAE) thioesters of type 5 (Fig. 1c).
SEAE thioesters 5, produced in situ from stable SEA thioester
surrogates of type 3 or 4, appear as a robust solution for the
implementation of NCL under microﬂuidic conditions
(Fig. 1b). Although not yet fully understood, the enhanced
reactivity proﬁle of SEAE peptide thioesters 5 toward NCL
enables extremely fast cyclization (<5 min) at notoriously
difﬁcult junctions (Val, Thr, or Ile), as well as intra or inter-
molecular ligations with the least tractable Pro junction.
The method enables the production of cyclic peptides of
varying size (10-28 AA), including biologically active RTD-1,
by the formation of diverse junctions (Val, Ile, Thr, Pro, Phe,
Tyr, Leu). We present concrete solutions for taming and
exploiting the enhanced reactivity of SEAE peptides, as well as
for implementing NCL under microﬂuidic conditions with
fast optimization of reaction parameters (temperature, resi-
dence time, pH, concentration, local stoichiometry). The
microﬂuidic NCL method described herein is complementary
to DSL by permitting the formation of peptide bonds to Cys.
It enables the seamless production of tens of milligrams of
cyclic peptide without special precautions, under fully auto-
mated operation easy to deploy, while guaranteeing a homo-
geneous purity proﬁle.
Results
Evidence for the high reactivity of SEAE peptide thioesters. A
typical batch experiment highlighting the difference in reactivity
between classical MPA peptide thioesters and SEAE thioesters is
the thiol-thioester exchange reaction with MPAA, which con-
stitutes the rate-limiting step of NCL with peptide alkylthioesters
(Fig. 2a, b). The yield for MPAA peptide thioester 2a from pre-
formed SEAE peptide 5a was 60% within 5 min, while the reac-
tion with MPA thioester 1a required ca 80 min to reach a similar
conversion (Fig. 2c, Supplementary Methods). In fact, further
kinetic studies under microﬂuidic conditions showed that the
conversion of SEAE peptide 5a into MPAA thioester 2a pro-
ceeded in less than 15 s, while the MPA peptide thioester analog
1a furnished only ~2% of MPAA thioester 2a after 15 s (Fig. 2d,
Supplementary Methods). Note that in the absence of a Cys
peptide, the SEA peptide amide 4a acts as a thermodynamic sink
according to Fig. 2b. Thus after an initial burst phase, MPAA
thioester 2a decreases over time. Note that the conversion of
MPAA thioester 2 or SEAE peptide 5 back into SEA peptide 4 is
greatly minimized under microﬂuidic conditions in the presence
of the Cys partner. A similar contrasting reactivity was observed
for peptide thioesters 1a or 5a upon NCL with a model Cys
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peptide in the presence of MPAA (Supplementary Fig. 1, Sup-
plementary Methods). A likely rationalization for the enhanced
reactivity of thioesters of type 5 involves the intramolecular
neighboring assistance (acid-catalysis) of the ammonium group
for the departure of thiolate 6 (Fig. 2e). This hypothesis relies on
the fact that the breakdown from the tetrahedral intermediate,
i.e., step 2 in Fig. 2e, is typically rate-limiting with simple alkyl-
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Fig. 1 Cyclic peptide synthesis using NCL and its implementation under microﬂuidic conditions. a Principle of NCL reaction applied to cyclic peptide
synthesis. The NCL reaction involves the chemoselective reaction of a C-terminal peptide alkylthioester (e.g., MPA peptide thioester 1) or arylthioester
(e.g., MPAA peptide thioester 2) with an N-terminal cysteinyl peptide. The intramolecular version of this reaction enables backbone cyclization. The
ligation proceeds in the presence of an exogenous thiol catalyst (typically MPAA) and a reductant (typically TCEP). b Implementation of NCL under
microﬂuidic conditions toward backbone peptide cyclization. The system is fed with a stable precursor, which is activated into a highly reactive thioester
species before entering the ligation module. c Reactive SEAE peptide thioesters are generated from the stable SEA cyclic disulﬁde (SEAoff) 3 upon
reduction with TCEP or from the reduced SEAon bisthiol 4. SEAE peptide thioesters 5 enable extremely fast NCL even with difﬁcult C-terminal amino acids
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Establishing feasibility. Having established the high reactivity
of SEAE peptide thioesters, we next designed a microﬂuidic
system featuring a three-stage process that includes (a) the
generation of SEAE intermediates 5 from SEA peptide amides 3
or 4 in the ﬁrst microﬂuidic module (stage 1 in Fig. 3), (b) the
conversion of SEAE peptide thioester 5 into MPAA peptide
thioester 2 followed by the intramolecular NCL in the second
module (stage 2 in Fig. 3), and ﬁnally (c) a post-ligation
treatment (stage 3 in Fig. 3). Figure 3 also details the various
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Fig. 2 Evidence for the enhanced reactivity of SEAE peptide thioesters. a Principle of the thiol-thioester exchange between MPA peptide thioester 1a and
MPAA. b Principle of the thiol-thioester exchange between SEAE peptide thioester 5a and MPAA. c Evidence for the high reactivity of model SEAE peptide
5a (circles ﬁlled with magenta) featuring a C-terminal difﬁcult amino acid (valine) in comparison with the classical MPA peptide thioester analog 1a (ﬁlled
triangles). The peptides were reacted in 0.2M sodium phosphate buffer (pH 7.0) containing 50mM TCEP and 400mM MPAA at 37 °C. The exchange
reaction was monitored by HPLC (UV detection at 215 nm). d Same reactions as in c under the optimal microﬂuidic conditions described in Fig. 4 (1a: black
triangles, 5a: magenta circles). e The high reactivity of SEAE peptide thioesters is potentially a consequence of an intramolecular acid-catalysis that
facilitates departure of thiol 6 from the tetrahedral intermediate (step 2). This step is rate-limiting for simple alkylthiols such as MPA. R’ and R” correspond
to the amino acid side-chain (see Fig. 1)
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The feasibility of the microﬂuidic strategy for cyclic peptide
synthesis according to Fig. 3 was assessed starting with a reduced
SEAon peptide 4. This allowed us to simplify the preliminary
attempts by avoiding the reduction of disulﬁde 3 into dithiol 4.
The equilibrium between SEAon amides 4 and SEAE peptides 5
considerably favors the amide at neutral pH to a point where SEAE
peptides 5 are barely detectable by HPLC39. In contrast, the
equilibrium favors the SEAE peptide 5 at pH 1 by ≥90% so that the
activation was examined at this pH. Based upon preliminary data
obtained in batch with model tetrapeptide TASV-SEAon 4b
(Supplementary Fig. 2, Supplementary Methods), it turned out
that the most balanced conditions for implementation in a
microﬂuidic system required 90 °C and 60min of reaction time
(~90% conversion) for a difﬁcult C-terminal amino acid such as
Val. Pivotal adaptations for an implementation in ﬂow were
required since the reaction is sensitive to residence time distribution
(Fig. 4a)40,41. The use of an immiscible carrier (decane, feed
solution 2), as well as the insertion of a back pressure regulator
(BPR) markedly improved the efﬁciency of the rearrangement
process under microﬂuidic conditions with yields in the 81–94%
range for peptides 7c,d for example (Supplementary Fig. 12 and 39,



















































































































Fig. 3 Fast intramolecular NCL toward macrocyclic peptide constructs. Details of the three-stage (activation–ligation–post ligation treatment) microﬂuidic
process allowing intramolecular NCL at non-problematic junctions (Leu (L), R′=−CH2CH(CH3)2, R′′=H; Tyr (Y), R′=−CH2Ph-p-OH, R′′=H), difﬁcult
junctions (underlined, Val (V): R′=−CH(CH3)2, R′′=H; Thr (T): R′=−CH(CH3)(OH), R′′=H; Ile (I): R′=−CH(CH3)(CH2CH3), R′′=H) and intractable
proline junction (bold, Pro (P): R′= R′′=−(CH2)3−). Two microﬂuidic modules (µF) are concatenated. In microreactor element µF1 (Activation, stage 1),
the feed solution containing an inactive and stable peptide precursor, SEAoff 3 or SEAon 4, is thermally rearranged at pH 1 to give reactive SEAE thioester 5.
In microreactor element µF2 (SEAE-MPAA exchange and intramolecular ligation, stage 2), reactive SEAE thioester 5 cyclizes directly into peptide 7 or is
converted into MPAA thioester 2 which then cyclizes into peptide 7. Depending on the conditions, amine dithiol 6 can become a competing nucleophile
and convert MPAA thioester 2 back to SEAon peptide 4. The last stage (Post ligation treatment, MPAA extraction and HPLC puriﬁcation, stage 3) enables
the isolation of the cyclic peptide
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ba
Feed solution 1
Peptide 4 (7 mM)
TCEP (100 mM), pH 1
Workup 1 (all)
BPR 2.5 bar
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t2 = 4 min
Fig. 4 Optimized microﬂuidic setup. a Details of the optimized microﬂuidic system. The pH of the MPAA feed solution was set at 7.80, leading to an
optimum internal pH of 7.3 within microﬂuidic element µF2, and the residence time t2 to 4min. ϕ1 = ϕ2 = 3.3 µL min−1, ϕ3 = 35 µL min−1. The back
pressure regulator (BPR) was set at 2.5 bars. The peptide concentration in the Feed solution 1 was 7mM. For 7c, the reactor efﬂuent was quenched in
10% aqueous acetic acid. MPAA was then extracted with diethylether (5×) before HPLC analysis and puriﬁcation (workup 1). For 7d-k, the cyclic peptide
co-eluted by HPLC with the starting SEAon peptide 4. Therefore, the reactor efﬂuent was treated ﬁrst with AcA-MPA 8/TCEP dissolved in pH 7.4
phosphate buffer (workup 2) and then according to workup 1. 1 Isolated yields after HPLC puriﬁcation. R′ and R′′ are for side-chain amino acids (see Fig. 1).
b Representative HPLC chromatogram for cyclized peptide 7d after workup 1 (top) or workup 2 and 1 (bottom)
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We also demonstrated that the microﬂuidic system can be fed
with SEAoff peptides of type 3 as well. Batch experiments using
tetrapeptide TASV-SEAoff 3b established that SEAoff peptides of
type 3 are refractory to reduction by tris(2-carboxyethyl)
phosphine (TCEP) at pH 1 at room temperature, while reduction
proceeds rapidly at 90 °C (Supplementary Fig. 3, Supplementary
Methods). Therefore, when SEAoff peptides 3 are used in the feed
solution 1, both reduction (3→4) and activation (4→5) steps
proceed in the ﬁrst microreactor (µF1, Supplementary Methods).
Both types of precursors are easily accessible through 9-
ﬂuorenylmethyloxycarbonyl (Fmoc) SPPS (Supplementary Meth-
ods)42. Finally, we established that the temperature in µF1
could be lowered to 65 °C for the rearrangement of peptides
terminated by non-problematic amino acids such as leucine
(Leu, L; Fig. 4a; Supplementary Fig. 10 and 11), tyrosine (Tyr, Y;
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Fig. 5 Expanding the strategy to antimicrobial peptide RTD-1. a Three different junctions were assessed for the synthesis of RTD-1. The formation of
intermediate thiolactone species imposed some adaptation to the optimal conditions deﬁned in Fig. 4a: the residence time and temperature in µF2 were
increased from 4 to 15min and from 37 to 45 °C. b Representative HPLC chromatogram for RTD-1 synthesis from peptide 4n. c Antibacterial activity of
folded RTD-1 produced from 4m against E. coli BW 25113 (ﬁlled triangles) and S. aureus SH 1000 strains (open triangles). The experiment was done in
triplicate. The data correspond to the mean and standard deviation of the log10 transformed colony-forming units (cfu) per mL. The limit of detection is
100 cfumL−1
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We next focused our efforts towards the SEAE-MPAA
exchange reaction and the cyclization process under microﬂuidic
conditions (stage 2 in Fig. 3, Fig. 4a). The ﬁrst experiments were
carried out using HIV polymerase-derived model peptide 4c. Its
cyclization toward c-(CILKEPVHGV) 7c thus comes with a
difﬁcult junction, i.e., Val-Cys. Following the activation step, the
acidic SEAE peptide thioester 5c solution must be quickly mixed
with the exogenous arylthiol MPAA. Since the pH in the second
microﬂuidic module determines the kinetics of NCL43, as well as
those of the undesirable deactivation of 5c into 4c, it was
mandatory to identify the optimal pH for this step. pH
optimization was realized with a dedicated system having two
separate feeds of MPAA and sodium hydroxide after the activation
module µF1, the relative ﬂow rate of which enabled tuning the pH
in the microﬂuidic element µF2 from 7.2 to 8.2 (Supplementary
Methods). This study showed that conversion reached a
maximum at pH ~7.3 and decreased almost linearly upon pH
increase (Supplementary Fig. 23). At pH > 7.3 the fraction of
amide 4c in the mixture gradually increased, thus decreasing the
yield of cyclic peptide 7c. This study demonstrated the paramount
importance of the precise control of the reaction conditions for
such ligations. Subsequently, the two feeds of NaOH and MPAA
were replaced by a single feed of MPAA giving the optimal pH of
7.3 in µF2 after mixing with the efﬂuent from µF1 (Fig. 4a).
Kinetic study and suppression of dimeric species. A kinetic
study of the process was next carried out by adjusting the internal
volume of module µF2 using the optimized pH conditions to
screen residence times from 30min down to 1 min. This
experiment revealed that the reaction time had very little impact
on the production of c-(CILKEPVHGV) 7c, except for the
shortest residence time of 1 min for which the reaction did not
reach completion (Supplementary Fig. 24, Supplementary Meth-
ods). Most notably, reaction completion was observed within 2
min of residence time. In further experiments, a safety margin
was included and the residence time was set at 4 min. Dimeric
linear or cyclic species were also identiﬁed in the efﬂuent at this
occasion (Supplementary Fig. 24 and 25, Supplementary Meth-
ods). A two-fold dilution of the feed solution of peptide 4c suf-
ﬁced to suppress their formation. This updated setup allowed the
preparative synthesis of cyclic peptide 7c with an isolated yield of
46% following addition of an acetic acid quenching solution,
MPAA extraction and HPLC puriﬁcation (Fig. 4a, workup 1,
Supplementary Methods).
Advantages of SEAE chemistry under microﬂuidic conditions.
With an optimal microﬂuidic system in hand, we sought to
examine the advantage of using SEAE peptide thioesters in
comparison with classical MPA or MPAA peptide thioesters 1 or
2 for peptide cyclization under microﬂuidic conditions. We also
evaluated the beneﬁt of performing the cyclization under
microﬂuidic conditions over classical batch procedures.
The impact of the type of acyl donor on the efﬁciency of the
cyclization process was studied by telescoping MPA peptide
thioester CILKEPVHGV-MPA 1c (Supplementary Fig. 18, Sup-
plementary Methods) or MPAA peptide thioester CILKEPVHGV-
MPAA 2c (Supplementary Fig. 18 and 27, Supplementary
Methods) dissolved at pH 1 with the MPAA feed solution 3.
LC–MS analysis of the efﬂuent after 4 min of residence time
showed a poor conversion of MPA peptide thioester
CILKEPVHGV-MPA 1c into cyclic product 7c (11%, Supple-
mentary Fig. 26). Moreover, peptide 7c was contaminated by some
MPAA peptide thioester 2c and dimeric species. Comparatively,
the reaction with MPAA peptide thioester 2c was more advanced,
yet still incomplete, and the formation of some dimeric species
was also observed in this case (Supplementary Fig. 28). Although
MPAA was found to be essential for the cyclization process
(Supplementary Fig. 4, Supplementary Methods), the latter
experiment showed that the use of preformed MPAA peptide
thioester 2c could not reproduce similar high performances for
reaction rate and purity proﬁle as obtained when the microﬂuidic
system was fed with SEAon peptide 4c. This suggests that part of
the cyclic peptide 7c is produced by the direct cyclization of SEAE
peptide 5c (Fig. 2). Therefore, the fast cyclization rate is due to the
combined high reactivity of SEAE and MPAA peptide thioesters.
Next, peptide 4c was also used to compare the assets of the
microﬂuidic protocol versus a conventional batch procedure.
Operation at steady state for over 3 h with the optimized
microﬂuidic setup furnished consistent results with a homo-
genous purity proﬁle for cyclic peptide 7c, thus demonstrating the
scale-independent nature of the process, as well as its stability
(Supplementary Fig. 29, Supplementary Methods). In contrast,
batch experiments on three different scales (10-, 25-, and 50-mg-
production scales) provided inconsistent results with higher
impurity contents (mainly unreacted peptide thioester and
dimeric species, Supplementary Fig. 6 and 7, Supplementary
Methods) than the corresponding microﬂuidic experiments.
Taken altogether, these experiments show that while the high
reactivity of SEAE peptide thioesters has a major contribution to
the rate of cyclization, this proceeds even faster under micro-
ﬂuidic conditions and with a higher purity proﬁle compared to
classical batch procedures.
Exploring the peptide sequence dependency. We next examined
the scope of the microﬂuidic process by varying some internal
residues, the C-terminal amino acid bearing the SEAE function-
ality, and peptide length. Concerning the role of internal residues,
several studies have shown that a proline can favor the backbone
cyclization of protected peptides in organic solvents by classical
activation procedures44. Indeed, the cis conformation of the
peptide bond to proline is signiﬁcantly more frequent (typically
~9% for Glu-Pro as in peptide 4c) than for the other amino acids
(<0.1%)45, thereby introducing a kink in the peptide chain and
bringing the reactive ends closer in space. To evaluate the role of
Pro6 on the cyclization of peptide 4c, the microﬂuidic system was
fed with analog 4d, in which Pro6 was changed to Gly. The
activation of 4d into 5d proceeded with a conversion of 94% in
module µF1, comparable to the results obtained with the original
model 4c. The intramolecular cyclization module µF2 was tele-
scoped to µF1, but co-elution of cyclic peptide 7d and the starting
SEAon peptide 4d precluded direct determination of an HPLC
conversion. To solve this, the reactor efﬂuent was treated with an
excess of 3-((3-oxobutanoyl)thiol)propanoic acid (AcA-MPA 846)
that reacted quantitatively with any remaining peptide 4d by NCL
at its N-terminal Cys. The resulting AcA peptide 9d was easily
separated from the cyclic peptide 7d by HPLC, thus allowing both
quantiﬁcation and puriﬁcation of cyclic peptide 7d (Fig. 4b).
Compared to the cyclization of 4c, a higher conversion of
c-(CILKEGVHGV) 7d was measured (Supplementary Table 10,
Supplementary Methods). Therefore and contrary to expecta-
tions44, in this case the presence of an internal proline in 4c had a
deleterious effect on the cyclization reaction.
We also examined the compatibility of the microﬂuidic system
with internal asparaginyl-glycyl (NG) or aspartyl-glycyl (DG)
dipeptide units, which are known to be particularly sensitive to
several side-reactions such as aspartimide formation, deamida-
tion, or peptide cleavage. Peptide 4e equipped with an internal
NG dipeptide unit and a C-terminal Val residue successfully
yielded cyclic peptide 7e with a higher yield than that obtained for
7c. Some deamidation of asparagine residue was nevertheless
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observed during the activation step at 90 °C (~15–20%,
Supplementary Fig. 8, Supplementary Methods). Comparatively,
Leu analog 4g was activated at 65 °C and cyclized without side-
reactions (Supplementary Fig. 10). In contrast, DG dipeptide in
peptide 4f unit suffered as expected from a partial cleavage during
the activation at 90 °C (Supplementary Fig. 9A). However, and
here again, the side-reactions were nearly suppressed by
performing the activation at 65 °C in the ﬁrst microﬂuidic
module (Supplementary Fig. 9B). Therefore, the activation of DG
peptides 4f and 4h terminated by Val and Leu residues,
respectively, was thus performed at 65 °C, albeit the activation
was less advanced in the former case.
We next examined the inﬂuence of the C-terminal residue,
which dictates the reactivity of peptide thioesters in NCL18. C-
terminal Thr, Val, and Ile are sterically demanding and
considered as difﬁcult amino acids. Proline is even more
problematic, and often considered as intractable47,48. In addition
to slow kinetics, NCL reactions with peptidyl prolyl thioesters are
also prone to side-reactions via deletion of two amino acids, i.e.,
the proline and the preceding residue, in the ligated product49,50.
This side-reaction is particularly pronounced when the C-
terminal Pro is preceded by Gly.
Peptides presenting a C-terminal Thr (4i) or Ile (4j) were
successfully cyclized into 7i and 7j, respectively, through the fully
concatenated setup and behaved similarly to peptides 4c,d
(Fig. 4a). For the Pro analog 4k, the activation into 5k was less
efﬁcient (66%). However, the intramolecular ligation step
proceeded with high efﬁciency within 4 min of residence time,
highlighting again the spectacular reactivity of SEAE thioesters in
NCL. To rule out the possibility that fast ligation kinetics are
simply a consequence of the intramolecular nature of the
reaction, a control experiment involving ILKEPVHGP-SEAon
4q in Feed solution 1 and peptide CILKEPVHGV-NH2 10 in
MPAA Feed solution 3 was carried out (Supplementary Table 13,
Supplementary Methods). The concatenated process was success-
fully operated using similar ligation conditions, and the peptide
product ILKEPVHGP-CILKEPVHGV-NH2 11 was isolated with
21% yield (28% corr.) after HPLC puriﬁcation within a few
minutes of ligation time, conﬁrming the spectacular reactivity of
SEAE peptides in NCL.
Note that due to its sequence, peptide 4k is potentially prone
to a deletion side-reaction. The deletion side-product, i.e.,
c-(CILKEGVH) 12, was indeed observed, but it accounted for
less than 8% of the total, showcasing the performance of the
microﬂuidic system for backbone cyclization of problematic
peptides. The slightly lower yield (38%) observed for 7k arose
from issues in separating the target peptide from the deletion
side-product. No signiﬁcant racemization was observed in the
ﬁnal products (Fig. 4a). Note that peptides 9d-k were isolated as
well and could potentially be recycled due to the easy removal of
the AcA group with hydroxylamine at pH 4.
Expanding the strategy to antimicrobial peptide RTD-1. We
next aimed at the preparation of a larger and biologically relevant
cyclic peptide, namely the 18 amino acid antimicrobial peptide
RTD-1 (Fig. 5a)51, which was produced from three different
precursors (4l-n), two of them involving the formation of a dif-
ﬁcult junction (4l: Val-Cys; 4m: Ile-Cys). Solubility issues in the
microﬂuidic element µF2 required the addition of a denaturing
agent (Gn·HCl, 6 M). We started with peptide SEAon 4l, which
was subjected to the complete microﬂuidic assembly using opti-
mized conditions identiﬁed above for difﬁcult junctions (Fig. 4a,
Supplementary Table 9, Supplementary Methods). LC–MS ana-
lysis of the crude product revealed the formation of RTD-1 in its
reduced form (49%), as expected, but also a large proportion
(34%) of side-products having the same mass as RTD-1. We
hypothesized that the side-products were macrocyclic thiolactone
species, the formation of which most likely involves a ring
expansion mechanism as discussed by Tam and coworkers
(Fig. 5a)52. To test this hypothesis, RTD-1 analog 4o, in which all
the Cys residues except the N-terminal one were changed to Ala,
was prepared (Fig. 2). The microﬂuidic experiment with peptide
4o furnished cyclic peptide c-(CRAIATRGFARALARRGV) 7o in
good isolated yield (HPLC yield 71%, isolated 37%) without side-
product formation. This suggests that the rearrangement of the
thiolactones formed by proximity-driven attack of internal
cysteine thiols on the C-terminal thioester, which ultimately
yields the backbone cyclized peptide by ring expansion, is rate-
limiting upon cyclization to RTD-1 under microﬂuidic condi-
tions. To promote the rearrangement of the thiolactone species,
we increased both the residence time (from 4 to 15 min) and the
temperature in module µF2 (from 37 to 45 °C). These microﬂuidic
conditions signiﬁcantly reduced the occurrence (<10%) of thio-
lactone species and increased the conversion of 4l into RTD-1
(71% HPLC yield, isolated yield 29%) accordingly. These condi-
tions were next successfully applied to peptide 4m (difﬁcult Ile-
Cys junction). In the case of RTD-1 precursor 4n, which has a
non-problematic C-terminal Phe residue, the activation in µF1
module was performed at 65 °C (Fig. 5b). Cyclization in module
µF2 proved to be highly efﬁcient although some epimerisation of
the Phe residue was noticed (4.9%). No thiolactone intermediates
remained in the crude reactor efﬂuent in this case. The higher
accessibility of the carbonyl group of Phe to thiol nucleophiles
compared to Val or Ile most likely allows a faster rearrangement
of intermediate thiolactone species. This example shows that the
microﬂuidic system can be easily tailored to the speciﬁc
requirements of a variety of junctions.
Native RTD-1 peptide is stabilized by three disulﬁde bonds,
which are important for the cyclic peptide to exhibit its full
biological activity. The reduced RTD-1 peptide is known to
spontaneously form the native pattern of disulﬁde bonds upon
oxidative folding51. Therefore, RTD-1 peptide produced from
peptide 4l was oxidized (Supplementary Methods)51, and tested
for its antibacterial activity against E. coli and S. aureus strains
(Fig. 5c, Supplementary Methods). The folded RTD-1 peptide
displayed the expected antibacterial activity in this assay, showing
the capacity of the microﬂuidic system to produce a cyclic peptide
of biological interest.
As a ﬁnal demonstration for this study, we performed the
cyclization of a longer peptide model sequence (28 mer, peptide
4p) derived from the hepatocyte growth factor (Fig. 2). Since this
peptide features a non-problematic C-terminal Tyr residue,
cyclization was performed using the microﬂuidic setup deﬁned
for RTD-1 precursor 4n (see Fig. 5a and Supplementary Fig. 82).
Cyclization proceeded efﬁciently by providing the target cyclic
peptide 7p with a 41% yield after HPLC puriﬁcation.
Discussion
The design of highly reactive peptidyl donors and extremely fast
ligation methods is a timely and signiﬁcant goal. Such chemical
tools can streamline the production of complex peptides and
especially those implicating the formation of difﬁcult junctions.
Importantly, fast ligation methods potentially open the way
toward peptide production under microﬂuidic conditions. How-
ever, to beneﬁt from all the well-established assets of continuous
ﬂow operation, the issues related to using and controlling highly
reactive peptidyl donors must be overcome. Ideally, such reactive
species should be generated in the microﬂuidic system to avoid
their isolation, storage, and handling. In this regard, the micro-
ﬂuidic NCL procedure reported herein constitutes a signiﬁcant
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advance for peptide chemical ligation under homogeneous con-
ditions by providing a straightforward and operationally simple
method to exploit the enhanced reactivity of SEAE peptidyl
thioesters at their fullest. The procedure relies on a highly mod-
ular microﬂuidic system that enables progressive activation
starting from stable and readily available peptide amides. The
highly integrated nature of the microﬂuidic system greatly sim-
pliﬁes peptide cyclization in a scale-independent and automated
manner. Several production campaigns sustained the production
of high-quality materials with only small variations. Attempts to
reproduce similar performance with a batch setup provided
inconsistent results with higher impurity contents.
Short cyclative ligation rates (<4 min) were obtained even for
difﬁcult (Val, Ile, and Thr) and the most intractable (Pro) junc-
tions. The high reactivity of SEAE peptidyl thioesters cannot be
deduced from previous studies that involved simple thioester
functionalities38. In addition, reports dealing with the impact of
the thiol backbone on the reactivity of the corresponding thioe-
ster remain scarce53,54. Recently, a few studies unveiled the
positive impact of non-proteinogenic C-terminal thiol amino
acids on thioester reactivity18,55,56. Our approach is particularly
appealing since it does not require the modiﬁcation of the peptide
structure and post-ligation chemical transformations. It relies on
robust chemistry amenable to conventional SPPS for the pre-
paration of the starting SEA peptide fragments. The high reac-
tivity of SEAE peptidyl thioesters should stimulate further work
with the objective of understanding how chemical groups internal
to the thioester peptide can dramatically boost its reactivity.
In summary, the chemistry and microﬂuidic system described
in this study are ﬂexible and versatile, and could be easily adapted
to the inherent speciﬁcities of various cyclic peptides. This work
provides the preliminary step towards the development of a
generalized microﬂuidic procedure for the scale-independent
production of cyclic peptide architectures, as well as post-ligation
cosmetic operations (desulfurization, oxidative folding). The
procedure makes peptide cyclization much more accessible,
particularly for preparative applications.
Methods
Reagents. 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium ﬂuorophosphate
(HBTU) and N-Fmoc protected amino acids were obtained from Iris Biotech
GmbH. 4-Mercaptophenylacetic acid (97%, MPAA), 3-mercaptopropionic acid
(MPA), tris(2-carboxyethyl)phosphine hydrochloride (≥98%, TCEP), thiophenol,
triisopropylsilane (TIS), guanidine hydrochloride (≥99%), sodium phosphate
dibasic dihydrate (≥99%), hydrochloric acid (reagent grade, 37%), and sodium
hydroxide (pellets, 97%) were purchased from Sigma-Aldrich. All other reagents
were purchased from Acros Organics or Merck and were of the purest grade
available. Peptide synthesis grade N,N-dimethylformamide, dichloromethane,
diethylether, acetonitrile, heptane, LC–MS-grade acetonitrile (0.1% TFA), LC–MS-
grade water (0.1% TFA), N,N-diisopropylethylamine (DIEA), and acetic anhydride
were purchased from Biosolve and Fisher-Chemical. Triﬂuoroacetic acid (TFA)
was obtained from Biosolve. Decane (synthesis grade) was purchased from Merck.
Solvents and reagents were used as received. Water was puriﬁed with a Milli-Q
UltraPure Water Puriﬁcation System.
Peptide synthesis. SEAon peptides 4c-p were synthesized from SEA polystyrene
resin using classical Fmoc SPPS protocols37. In brief, amino acids (10 equiv.) were
activated using HBTU (9.5 equiv.)/DIEA (10 equiv) in DMF. The peptidyl resin
was acetylated after each coupling step using acetic anhydride (10% by vol) and
DIEA (5% by vol.) in DMF. The removal of the Fmoc group was performed by
treating the peptidyl resin with piperidine (20% by vol.) in DMF. The peptides were
deprotected and cleaved from the resin using TFA/water/TIS/thiophenol cocktail
(92.5/2.5/2.5/2.5 by vol.). The crude SEAon peptides 4c-k were used without further
puriﬁcation. SEAon peptides 4l-p were puriﬁed by reversed-phase HPLC prior to
cyclization.
Microﬂuidic modules. Microﬂuidic modules were constructed with commercially
available elements from IDEX/Upchurch Scientiﬁc, including high purity PFA
capillaries, connectors, ferrules, static micromixers, and in-line check-valves
(Supplementary Tables 1 and 2). High force syringe pumps (Nexus 6000) for feed
delivery were purchased from Chemyx, and the dome-type BPR was purchased
from Zaiput Flow Technologies (Supplementary Methods).
Optimized microﬂuidic setup. The microﬂuidic ligation setup consisted of two
microﬂuidic modules constructed from high purity PFA capillary (µF1= 400 µL
internal volume and µF2= 170 µL internal volume) ﬂuidically connected in series
(Supplementary Fig. 17, Supplementary Methods). The temperature of µF1 was set
at 90 °C or 65 °C, and µF2 was operated at 37 °C or 45 °C (Supplementary Table 8
and 9). The ligation setup was operated with a counter-pressure of 2.5 bar. Static
mixers were utilized upstream module µF1 for establishing the segmented regime
prior to the activation step and upstream µF2 for the injection of the MPAA feed
solution for the ligation step (Supplementary Fig. 12 and 17, Supplementary
Methods).
Typical microﬂuidic ligation procedure. The ﬁrst module (µF1) was con-
comitantly fed with a solution of the desired starting SEAon peptide 4 (pH 1) and
n-decane (ﬂow rate= 3.3 µLmin−1 for each). The efﬂuent of µF1 was then mixed
with a solution of MPPA (ﬂow rate= 35 µLmin−1, pH 7.8), and the resulting
reaction mixture (pH 7.3) was conveyed to the second module (µF2). Details of the
procedures can be found in Supplementary Methods. The reactor efﬂuent was
collected at steady state, and processed. Speciﬁc downstream puriﬁcation proce-
dures including post-ligation procedures, MPAA extraction, and HPLC puriﬁca-
tion were established for each peptide sequence.
Typical post-ligation procedures. Workup 1 was used for peptides 7c, 7l-p
(Supplementary Methods). The reactor efﬂuent was collected in a 10% aqueous
acetic acid solution. MPAA was extracted 5 times with diethylether. The aqueous
solution was analyzed by HPLC or LC–MS and subsequently puriﬁed by HPLC.
Workups 2 and 1 were used for peptides 7d-k. For workup 2 (Supplementary
Methods), the reactor efﬂuent was collected in a solution of AcA-MPA46 (8, 1.2
equiv.) and TCEP.HCl (100 mM) in sodium phosphate buffer (0.2 M, pH= 7.4),
and maintained overnight at room temperature under a nitrogen atmosphere. The
corresponding reaction mixture was next treated according to workup 1.
Peptide puriﬁcation. The peptides were puriﬁed by reversed-phase HPLC on a
C18 column using a linear gradient of increasing concentration of eluent B in
eluent A (eluent A: 0.1% by vol. of triﬂuoroacetic acid (TFA) in water; eluent B:
0.1% vol. of TFA in acetonitrile/water: 4/1 by vol., ﬂow rate of 6 mLmin−1, UV
detection at 215 nm). The selected fractions were then combined, frozen, and
lyophilized.
Peptide characterization. The peptides were characterized by analytical LC–MS
on a reversed-phase XBridge BEH300 C18 column (3.5 μm, 300 Å, 4.6 × 150 mm)
at 30 °C using a linear gradient: 0–100% of eluent B in eluent A over 30 min at a
ﬂow rate of 1 mLmin−1. The column eluate was monitored by UV at 215 nm, by
evaporative light scattering or by electrospray ionization mass spectrometry (ESI-
MS). MALDI-TOF mass spectra were recorded with a Bruker Autoﬂex Speed using
alpha cyano 4-hydroxycinnaminic acid, sinapinic acid or 2,5-dihydroxybenzoic
acid (DHB) as matrix.
Kinetic studies. The aliquots (2 µL) were quenched with aqueous acetic acid (10%
by vol., 100 µL). MPAA was removed by extracting the aqueous phase with die-
thylether (5 times). The samples were then analyzed by LC–MS using a
C18XBridge column as described above in the Methods section: peptide
characterization.
RTD-1 antibacterial activity. E. coli BW25113 (kindly provided by Coli Genetic
Stock Centre, CGSC), and S. aureus SH1000 (kindly provided by Prof. S.J. Foster,
University of Shefﬁeld) were grown overnight in Cation-Adjusted Mueller Hinton
II Broth (37 °C, 150 rpm)51. Cultures were then diluted 1 in 20 and grown for 2 h
(37 °C, 150 rpm) to obtain a log phase bacterial culture. Log phase cultures were
then pelleted (3000× g, 5 min) and washed twice in 10 mM PIPES (pH 7.4) with
5 mM glucose. The bacterial suspension was diluted in piperazine-N,N′-bis(2-
ethanesulfonic acid) buffer (10 mM, pH 7.4) with 5 mM glucose to an optical
density of 0.00125 at 600 nm. A volume of 150 µL of the bacterial suspensions were
added to the wells of a 96-well plate. A volume of 3 µL of RTD-1 serially diluted in
water (at 50 × ﬁnal concentration, 800–25 µg mL−1) was then added to the bacteria
to give a ﬁnal concentration range of 16–0.5 µg mL−1. Bacteria viability was then
determined by counting colony-forming units following plating on LB agar.
Data availability. All relevant data are included in the manuscript and Supple-
mentary Information. More data are available from the authors upon request.
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